AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%

ANGIODYNAMICS INC

2025-FY EPS reported -$0.83 revenue$292,498,000

Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
Full year pro forma net sales $292.7M, up 8.1%; adjusted EBITDA positive at $7.6M.
Cash balance $55.9M; entered $25M revolving credit facility with J.P. Morgan.
Received CPT Category I code for NanoKnife IRE for pancreatic lesions, effective Jan 2027.
FY2026 guidance: net sales $305-310M; pro forma adjusted EBITDA $3-8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.